Buy Braftovi in India — Price & Availability

Braftovi’s prescribing information includes the following key warnings and precautions:
New primary malignancies: new skin cancers (cutaneous) and non-cutaneous cancers can occur; report any new or changing skin lesions promptly.
Tumour promotion in BRAF wild-type tumours: Braftovi is not used in wild-type BRAF cancers, as it may promote their growth.
Cardiomyopathy: heart function (ejection fraction) is monitored.
Hepatotoxicity: liver enzymes are monitored during treatment.
Hemorrhage, uveitis (eye inflammation), and QT prolongation: monitored and managed as needed.
Embryo-fetal toxicity: Braftovi can harm an unborn baby; effective contraception is advised, and non-hormonal methods may be recommended since encorafenib can reduce the effectiveness of hormonal contraceptives.

Common side effects:
Common side effects vary by regimen and may include fatigue, nausea, vomiting, diarrhoea, abdominal pain, joint and muscle pain, headache, rash and other skin changes, and altered blood tests. This is not a complete list — refer to the full prescribing information and your oncologist.

Braftovi’s prescribing information includes the following key warnings and precautions:

• New primary malignancies: new skin cancers (cutaneous) and non-cutaneous cancers can occur; report any new or changing skin lesions promptly.
• Tumour promotion in BRAF wild-type tumours: Braftovi is not used in wild-type BRAF cancers, as it may promote their growth.
• Cardiomyopathy: heart function (ejection fraction) is monitored.
• Hepatotoxicity: liver enzymes are monitored during treatment.
• Hemorrhage, uveitis (eye inflammation), and QT prolongation: monitored and managed as needed.
• Embryo-fetal toxicity: Braftovi can harm an unborn baby; effective contraception is advised, and non-hormonal methods may be recommended since encorafenib can reduce the effectiveness of hormonal contraceptives.

Common side effects: Common side effects vary by regimen and may include fatigue, nausea, vomiting, diarrhoea, abdominal pain, joint and muscle pain, headache, rash and other skin changes, and altered blood tests. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Braftovi through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Import & delivery — Braftovi is sourced and shipped under validated, temperature-controlled conditions to the patient or treating hospital.

Documents required to import Braftovi:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including BRAF V600E/V600K mutation test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Braftovi is not sold on the open market in India, there is no fixed MRP. The Braftovi cost in India depends on a few factors at the time of import:

• The number of 75 mg capsules and the pack size required per cycle, which is based on the prescribed daily dose (this varies by indication — for example, 450 mg once daily in melanoma and 300 mg once daily in colorectal cancer).
  The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Braftovi cost, logistics, and delivery timeline once a valid prescription is shared. Request your Braftovi quote →

Braftovi is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Braftovi from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. Braftovi capsules are stored at room temperature, 20 °C to 25 °C (68 °F to 77 °F), with excursions permitted between 15 °C and 30 °C, in the original bottle. Braftovi is moisture-sensitive: keep the container tightly closed, do not remove the desiccant, and protect from moisture. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Braftovi available in India?

Braftovi (encorafenib capsules) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Braftovi is not commercially marketed in India.

However, patients in India can legally access Braftovi through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Braftovi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Braftovi price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada,
• Europe, and Australia
  Ensuring full transparency throughout the process

Braftovi can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Braftovi first received US FDA approval on 27 June 2018, in combination with binimetinib, for BRAF V600E/V600K-mutated unresectable or metastatic melanoma. The FDA later approved it for BRAF V600E-mutated metastatic colorectal cancer (2020, with cetuximab; with a 2024 accelerated approval and subsequent traditional approval for the cetuximab plus chemotherapy regimen) and for BRAF V600E-mutated metastatic NSCLC (October 2023, with binimetinib). It is also approved in the European Union and other markets. As of the current publicly available information, Braftovi is not commercially marketed in India, which is why the Named Patient route is used.

How does Braftovi Import in India work?

Braftovi Import in India can be done through the Named Patient Program (NPP). This means the medicine can be imported on behalf of the patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How can I buy Braftovi in India?

Braftovi is not commercially marketed in India, but it can be legally accessed through the Named Patient Program. With a valid oncologist’s prescription, diagnostic reports (including BRAF mutation test results), and a government-issued patient ID, Indian Pharma Network facilitates compliant import in the patient’s name.

What is the price of Braftovi in India?

Braftovi is not sold on the open market in India, so the cost depends on sourcing, the number of capsules/packs required, logistics, and applicable duties at the time of import. A transparent, patient-specific quote is provided once the prescription is verified.

What is Braftovi used for?

It is used in combination with other medicines to treat BRAF V600E/V600K-mutated melanoma, BRAF V600E-mutated metastatic colorectal cancer, and BRAF V600E-mutated metastatic non-small cell lung cancer.

Who is a reliable Braftovi supplier in India?

Indian Pharma Network (IPN) is a trusted Braftovi supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

Who manufactures Braftovi?

Braftovi is manufactured by Pfizer (through its subsidiary Array BioPharma).

What is the dosage form and strength of Braftovi?

Braftovi is supplied as 75 mg hard gelatin capsules, taken orally. The daily dose depends on the indication (for example, 450 mg once daily in melanoma and NSCLC, and 300 mg once daily in colorectal cancer).

Who is an authorized Braftovi importer in India?

Indian Pharma Network (IPN) acts as a Braftovi importer in India. We help with Named Patient Import processes, regulatory documentation, and compliant procurement from leading international manufacturers for patients who need this therapy.

How is Braftovi stored and delivered?

Braftovi capsules are stored at room temperature in the original bottle, protected from moisture with the desiccant kept in place, and shipped under appropriate conditions to the patient or treating hospital.

Request Braftovi price & availability:

Speak with our patient support team for the Braftovi price, a transparent quote, and guidance on the Named Patient import process. We respond within 24 hours on business days.

• Call: +91-96548 60915
• WhatsApp: +91-98104 69557
• Toll-free: 1800-1200-365
• Email: info@indianpharmanetwork.in